DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20222747
Published: 2022-10-27

Cost variation analysis of commonly prescribed oral antipsychotic drugs available in India-a pharmacoeconomic perspective

Nivetha Raj R., Geetha A.

Abstract


Background: Antipsychotics are commonly prescribed for a variety of psychiatric disorders which require prolonged treatment. If a costly brand is prescribed, it reduces patient compliance, especially in the lower socio-economic groups. Awareness about the cost variation among different brands will guide an economically effective prescription by the treating physician.

Methods: The cost of different brands of commonly used oral antipsychotic drugs available in the Indian market manufactured by different companies, in the same strength, number and dosage form was obtained from the latest CIMS, MIMS, and India drug Index. The cost ratio and percentage cost variation were calculated for each. The cost for the same drugs was also noted from the Jan Aushadhi generic medicines portal and a comparison was made. 

Results: The percentage variation in the cost was above 100% with most of the commonly used antipsychotic drugs like haloperidol (517%), trifluoperazine (504.12%), risperidone (485.27%), chlorpromazine (436.35%), aripiprazole (340.34%), flupenthixol (293.12%), olanzapine (245%), ziprasidone (176.02%), amisulpride (169.44%), quetiapine (163.16%). Percentage cost variation between branded and generic drugs ranged from 400-1050%.

Conclusions: There is substantial cost variation among the various brands of antipsychotic drugs. Stigma surrounding generic prescription needs to be addressed. More psychiatric drugs need to be included under National list of essential medicines and DPCO (Drug price control order) so that there can be a ceiling on the maximum price.

 


Keywords


Antipsychotic drugs, Cost variation, Pharmacoeconomics

Full Text:

PDF

References


Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review. Schizophrenia Res. 2014;152(2):408-14.

Murthy RS. National Mental Health Survey of India 2015-2016. Ind J Psychiatr. 2017;59(1):21-6.

Pharmaceutical Companies in India, Indian Pharma Industry-IBEF. India Brand Equity Foundation. Available at: https://www.ibef.org/industry/ pharmaceutical-India. Accessed on 07 May 2022.

Srinivas I. The myth of branded generics. Economic and Political Weekly. 2014;12-5.

Basheer S. India’s tryst with TRIPS: the patents (amendment) act, 2005. Indian JL and Tech. 2005;1:15.

Acts and Rules. Available at: https://cdsco.gov.in/opencms/opencms/en/Acts-Rules/. Accessed on 07 May 2022.

Search Drug Information, Interactions, Images, Dosage and Side Effects | CIMS India. Available at: https://www.mims.com/india/. Accessed on 07 May 2022.

Pharmaceuticals & Medical Devices Bureau of India. Available at: http://janaushadhi.gov.in/. Accessed 07 May 2022.

National Pharmaceutical Pricing Authority. Department of Pharmaceuticals. Available at: https://pharmaceuticals.gov.in/national-pharmaceutical-pricing-authority. Accessed on 07 May 2022.

Shah NP, Chincholkar AS, Wagh RJ, Siddiqui WA. Cost variation analysis of antipsychotic drugs available in Indian market: an economic perspective. Int J Basic Clin Pharmacol. 2017;6(3):6848.

Shukla AK, Agnihotri A. Cost analysis of antipsychotic drugs available in India. Int J Basic Clin Pharmacol. 2017;6(3):669-74.

Charan J, Saxena D, Chaudhri M, Dutta S, Kaur RJ, Bhardwaj P. Opinion of primary care physicians regarding prescription of generic drugs: A Cross-sectional study. J Family Med Prim Care. 2021;10(3):1390-8.

Gandhi RJA. Consumer Perception of Generic Drugs in Comparison to Branded Drugs: A qualitative Study. Psychol Educ J. 2021;58(4):2388-98.

Gupta S, Nayak R, Vidyarthi S. A study on the knowledge, attitude, and the practice of generic medicines among the doctors in a tertiary care teaching hospital in South India. Natl J Physiol Pharm Pharmacol. 2015;5(1):39.